Ionis Pharmaceuticals, Inc.
ANTISENSE COMPOUNDS
Last updated:
Abstract:
Provided herein are gapmer oligomeric compounds for reduction of target RNA in vivo comprising different nucleotide modifications within one or both wing regions. Also provided are methods of using such oligomeric compounds, including use in animals. In certain embodiments, such compound have desirable potency and toxicity characteristics.
Status:
Application
Type:
Utility
Filling date:
21 Oct 2019
Issue date:
3 Sep 2020